Table VIII.
Clinical characteristics between patients with AML-M3 carrying the T allele, and those carrying the C allele.
| Patients with AML-M3 (T152C variation) | ||||
|---|---|---|---|---|
| Characteristic | Total (n=78) | T (n=46) | C (n=32) | P-value |
| Sex (female/male) | 31/47 | 23/23 | 8/24 | 0.026a |
| Age (years, mean ± SD) | 39.21±13.11 | 41.04±14.21 | 36.56±11.03 | 0.139 |
| Peripheral blood [median(P25-P75)] | ||||
| Hb (g/l) | 73.50 (63.75–103.00) | 73.50 (65.25–100.50) | 74.00 (57.75–110.50) | 0.851 |
| WBC (×109 cells/l) | 3.66 (1.44–11.25) | 2.81 (1.27–8.39) | 5.16 (2.04–17.24) | 0.065 |
| PLT (×109 cells/l) | 15.00 (10.00–29.00) | 13.50 (10.00–27.00) | 18.50 (10.75–31.25) | 0.427 |
| Hypocytosis, n (%) | 31 (39.7) | 19 (41.3) | 12 (37.5) | 0.785 |
| HLAL, n (%) | 5 (6.4) | 2 (4.3) | 3 (9.4) | 0.390 |
| PML-RARα, n (%) | 72 (92.3) | 41 (89.1) | 31 (96.9) | 0.392 |
| Chemotherapy responseb | ||||
| Remission at third month, n (%) | 53 (93.0) | 31 (91.2) | 22 (95.7) | 1.000 |
| Remission duration [days, median (P25-P75)] | 42.00 (34.00–60.00) | 44.00 (35.00–61.75) | 41.00 (34.00–57.00) | 0.782 |
a
OR, 3.000, 95% CI, 1.118–8.050
b
Completeclinical data were collected from 57 cases, 23 cases of which carried T152C variation. HLAL, hyperleukocytic acute leukemia; AML, acute myeloid leukemia; PML, promyelocytic leukemia; RARα, retinoic acid α receptor; WBC, white blood cell; PLT, platelet; Hb, hemoglobin; SD, standard deviation; OR, odds ratio; CI, confidence interval.